Lizzie, Toma, Jim Ellison discussed on On Point with Tom Ashbrook | Podcasts

Automatic TRANSCRIPT

With advanced stage three ovarian cancer, which statistically has a terrible survival rate. I'm like, I'll be very, very, very lucky if I'm still alive in five years and yet every day on NPR I hear about these clinics with all this immunotherapy, but there's nothing for me. And so my question to your researchers is for someone like me, how many years do I have to try to stay alive using conventional methods of treatment until someone comes up with therapy that's going to prolong my life? You know what I mean? Lizzy. Hang on. Don't don't hang up the phone here. Let me just turn to Jim Ellison. I Jim for her. One of the one of the excitement about immunotherapy is because there's a lot of cancers that that were uniformly fatal before that are now responding. Unfortunately, they don't all respond. I mean, the clear blessed Toma and pancreatic cancer, for example, that we hear about the news really have not responded much at all yet ovarian, his one which doesn't respond with the frequency we buy. And so what we're involved in here at an immune platform is really studying what goes wrong, not only in patients that have successful therapies, impatience that received combinations that don't work and try to figure out what's missing and then and then in irrational way at the things that are missing and try to, you know, move move it forward movement where it makes it more effective and you know we, we've done that in a few cancers now, but ovarian where he hit. We just have made it very far. Did I hear you correctly when you say that you've been searching for clinical trial to participate in, but you can't find one or one that you quote that will that you qualify for. Yeah, that's correct. I found one, but I don't think it's they're saying it's a vaccine, but it's like which they think is different from you know therapy, but it's also one where there's a fifty percent chance that will get a placebo. Now it's a pack seen same thing as therapy is that different Dr. It's different kinds of immunotherapy. Yeah, Monica avert you only I mean, what? What? What would you what guidance or advice would you have released? Because I imagine that there are many other people like her out there who would like to have access to these treatments even in the clinical trial phase, but for whatever reason cannot. Well, you know, you have two questions to issues first Lizzie. Thank you so much for calling in and for sharing your story with us because this is something that absolutely needs to be raised. Every time we have a discussion about some great breakthrough. There's just always so much more to do, and I hope very much that you are in an environment where you have expert doctors who are doing everything they can for you because you know, there's, there's a lot that can be done, but there's still a lot more to do now the issue of clinical trials. Again, Lizzie, thank you for illustrating that how the importance of that one of the things that one of the. A big problems. We have only three percent of patients adult patients in the United States participate in clinical trials. So ninety seven percent of people out there. We don't have information or even access to them for some of these new potential breakthrough therapies. So one of the big par things that we need to advocate for is more availability of clinical trials, and those trials need to get to every tiny community, not.

Coming up next